Skip to main content
. 2014 May 19;9(5):e96549. doi: 10.1371/journal.pone.0096549

Figure 5. Processing of mutated hybrid colicin E3/2 and E2/E3.

Figure 5

(A) Analysis of the in vivo observed forms derived from the hybrid-colicins. The proteins of the crude cell extracts of an ompT-inactivated strain (AD202; ΔompT), treated by colicin E3 (lanes 1, 5, E3), colicin E2 (lanes 4, 8, E2), hybrid colicin E2/E3 (lanes 2, 6) or hybrid colicin E3/E2 (lanes 3, 7), were separated on 15% SDS-PAGE and analysed in parallel by Western blotting with anti-colicin E2 antiserum (left panel) or anti-colicin E3 antiserum (right panel). (B) Colicin forms detected in vivo from mutated colicins, were analysed as described in (A). ColE2 PF was quantified and expressed as a percentage of PF value (%), measured with colicin E2 (lane 3, 100%).